Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

L. Akhuba; Z. Tigai; Dmitrii Shek

doi:10.20517/cdr.2022.142

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

L. Akhuba, Z. Tigai, Dmitrii Shek

Western Sydney University

Research output: Contribution to journal › Article › peer-review

Abstract

In 2030, pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related mortality in the world. Unfortunately, neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low. PDAC is notorious for its immuneresistant features and unique genomic landscape facilitating tumor escape from immunosurveillance. Novel immune-checkpoint inhibitors (ICI) failed to show promising efficacy and other multi-modal approaches are currently being validated in multiple clinical trials. In this paper, we provide our opinion on the major mechanisms responsible for PDAC resistance to ICI therapy and provide our view on future strategies which may overcome those barriers.

Original language	English
Pages (from-to)	327-331
Number of pages	5
Journal	Cancer Drug Resistance
Volume	6
Issue number	2
DOIs	https://doi.org/10.20517/cdr.2022.142
Publication status	Published - 2023

Open Access - Access Right Statement

© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Access to Document

10.20517/cdr.2022.142

Cite this

@article{3737092a616e46458a0695f17e4663f5,

title = "Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma",

abstract = "In 2030, pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related mortality in the world. Unfortunately, neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low. PDAC is notorious for its immuneresistant features and unique genomic landscape facilitating tumor escape from immunosurveillance. Novel immune-checkpoint inhibitors (ICI) failed to show promising efficacy and other multi-modal approaches are currently being validated in multiple clinical trials. In this paper, we provide our opinion on the major mechanisms responsible for PDAC resistance to ICI therapy and provide our view on future strategies which may overcome those barriers.",

author = "L. Akhuba and Z. Tigai and Dmitrii Shek",

year = "2023",

doi = "10.20517/cdr.2022.142",

language = "English",

volume = "6",

pages = "327--331",

journal = "Cancer Drug Resistance",

issn = "2578-532X",

publisher = "OAE Publishing",

number = "2",

}

TY - JOUR

T1 - Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

AU - Akhuba, L.

AU - Tigai, Z.

AU - Shek, Dmitrii

PY - 2023

Y1 - 2023

N2 - In 2030, pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related mortality in the world. Unfortunately, neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low. PDAC is notorious for its immuneresistant features and unique genomic landscape facilitating tumor escape from immunosurveillance. Novel immune-checkpoint inhibitors (ICI) failed to show promising efficacy and other multi-modal approaches are currently being validated in multiple clinical trials. In this paper, we provide our opinion on the major mechanisms responsible for PDAC resistance to ICI therapy and provide our view on future strategies which may overcome those barriers.

AB - In 2030, pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related mortality in the world. Unfortunately, neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low. PDAC is notorious for its immuneresistant features and unique genomic landscape facilitating tumor escape from immunosurveillance. Novel immune-checkpoint inhibitors (ICI) failed to show promising efficacy and other multi-modal approaches are currently being validated in multiple clinical trials. In this paper, we provide our opinion on the major mechanisms responsible for PDAC resistance to ICI therapy and provide our view on future strategies which may overcome those barriers.

UR - https://hdl.handle.net/1959.7/uws:74461

U2 - 10.20517/cdr.2022.142

DO - 10.20517/cdr.2022.142

M3 - Article

SN - 2578-532X

VL - 6

SP - 327

EP - 331

JO - Cancer Drug Resistance

JF - Cancer Drug Resistance

IS - 2

ER -

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

Abstract

Open Access - Access Right Statement

Access to Document

Other files and links

Fingerprint

Cite this